Health Care·Pharmaceuticals·$3.0B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.36 | N/A | -11.11% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.36 | N/A | -11.11% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed concern over recent performance but remains focused on future opportunities. They did not provide specific guidance for the upcoming quarters.
Management highlighted ongoing challenges in meeting financial expectations.
They emphasized their commitment to long-term growth despite current setbacks.
Nektar Therapeutics reported a loss that was slightly worse than expected, which typically raises concerns among investors. However, the stock rose by 2.04%, suggesting that investors may be optimistic about the company's long-term potential despite the current challenges. The lack of revenue data and guidance leaves some uncertainty about future performance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
AMKOR TECHNOLOGY INC
Aug 1, 2016